Cardiovascular disease is the leading cause of death worldwide. Despite advancements in
diagnosis and treatment of cardiovascular disease, the incidence of cardiovascular disease …

Kinase inhibitors have transformed the treatment of many cancers and are showing the
same promise for other indications including inflammatory diseases. This class of drugs is …

Background Breast cancer stem cells (CSCs) are small sub-type of the whole cancer cells
that drive tumor initiation, progression and metastasis. Recent studies have demonstrated a …

Renal cell carcinoma (RCC) represents the main renal tumors and are highly metastatic.
Sunitinib, a recently-approved, multi-targeted Tyrosine Kinases Inhibitor (TKi), prolongs …

BACKGROUND: Aberrant amino acid metabolism is implicated in cardiac hypertrophy, while
the involvement of tryptophan metabolism in pathological cardiac hypertrophy remains …

BACKGROUND The outcome of clear cell renal cell carcinoma (ccRCC) is still
unpredictable. Even with new targeted therapies, the average progression-free survival is …

Growing evidence indicates that there is an emerging link between environmental pollution
and cardiac hypertrophy, while the mechanism is unclear. The objective of this study was to …

Drug-induced cardiotoxicity may be modulated by endogenous arachidonic acid (AA)–
derived metabolites known as epoxyeicosatrienoic acids (EETs) synthesized by cytochrome …

Carfilzomib is a proteasome inhibitor, commonly used in multiple myeloma, but its clinical
use may be limited due to cardiotoxicity. This study was aimed to evaluate the influence of …

Sunitinib, a multitargeted oral tyrosine kinase inhibitor, used widely to treat solid tumors,
results in hypertension in up to 47% and left ventricular dysfunction in up to 19% of treated …